---
title: "Top 10 HK Stock Losers (11.19)"
description: "QFIN-S(03660) fell 11.47%, with a trading turnover 18.6 Million HKD, and a year-to-date fell 45.7%. BIOCYTOGEN-B(02315) fell 8.84%, with a trading turnover 34.3 Million HKD, and a year-to-date rose 25"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/266502728.md"
published_at: "2025-11-19T08:30:42.000Z"
---

# Top 10 HK Stock Losers (11.19)

> QFIN-S(03660) fell 11.47%, with a trading turnover 18.6 Million HKD, and a year-to-date fell 45.7%. BIOCYTOGEN-B(02315) fell 8.84%, with a trading turnover 34.3 Million HKD, and a year-to-date rose 256.5%. CHINA HK POWER(00931) fell 7.53%, with a trading turnover 23.0 Million HKD, and a year-to-date rose 16.2%.

Hang Seng Index has fell 0.38%, with a year-to-date rose 28.8%; Hang Seng TECH Index has fell 0.69%, with a year-to-date rose 25.5%.

QFIN-S(03660) fell 11.47%, with a trading turnover 18.6 Million HKD, and a year-to-date fell 45.7%.

BIOCYTOGEN-B(02315) fell 8.84%, with a trading turnover 34.3 Million HKD, and a year-to-date rose 256.5%.

CHINA HK POWER(00931) fell 7.53%, with a trading turnover 23.0 Million HKD, and a year-to-date rose 16.2%.

### Related Stocks

- [03660.HK - QFIN-S](https://longbridge.com/en/quote/03660.HK.md)
- [02315.HK - BIOCYTOGEN-B](https://longbridge.com/en/quote/02315.HK.md)
- [00931.HK - CHINA HK POWER](https://longbridge.com/en/quote/00931.HK.md)
- [02579.HK - CNGR](https://longbridge.com/en/quote/02579.HK.md)
- [02591.HK - INNOGEN-B](https://longbridge.com/en/quote/02591.HK.md)
- [00326.HK - CHINA STAR ENT](https://longbridge.com/en/quote/00326.HK.md)
- [01931.HK - ETHK LABS INC.](https://longbridge.com/en/quote/01931.HK.md)
- [02096.HK - SIMCERE PHARMA](https://longbridge.com/en/quote/02096.HK.md)
- [02245.HK - LYGEND RESOURCE](https://longbridge.com/en/quote/02245.HK.md)
- [00638.HK - FIBOCOM](https://longbridge.com/en/quote/00638.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 百奧賽圖-B 制定董事會結構及委員會職能 | 百奧賽圖（北京）生物醫藥有限公司宣佈了其董事會結構，由董事長兼首席執行官沈躍雷博士領導，包括多個董事職務。公司已成立四個關鍵委員會：審計委員會、薪酬與評估委員會、提名委員會和戰略發展委員會，旨在增強公司治理和戰略規劃。百奧賽圖股票（HK:2 | [Link](https://longbridge.com/en/news/275756980.md) |
| 百奧賽圖（北京）生物製藥有限公司宣佈 2026 年首次臨時股東大會的日期 | 北京百奧賽圖製藥有限公司將於 2026 年 2 月 12 日在其大興生物醫藥產業園舉行第一次臨時股東大會，並提供在線訪問。股東將對劉洪康先生擔任非執行董事的提名進行投票。該公告通過香港證券交易所的發行人信息服務發佈 | [Link](https://longbridge.com/en/news/273877900.md) |
| 中偉新材股東在 2026 年股東特別大會上批准了外部財務援助計劃 | 中偉新材（CNGR Advanced Material Co., Ltd.）於 2026 年 2 月 12 日召開了特別股東大會，代表 53.47% 表決股份的股東以超過 99.9% 的贊成票通過了一項外部財務援助計劃。會議經過獨立審查和法 | [Link](https://longbridge.com/en/news/275804927.md) |
| 廣和通無線公佈 2026 年員工持股計劃 | Fibocom Wireless Inc. 提出了 2026 年員工持股計劃（ESOP），待在特別股東大會上獲得批准。該計劃已獲得董事會批准，將使員工能夠獲得 Fibocom 的 A 股。董事會尋求授權以管理所有相關事務，並建議股東投票支持 | [Link](https://longbridge.com/en/news/275374950.md) |
| 百奧賽圖預計 2025 年因海外擴張和行業復甦將實現利潤大幅增長 | 北京百奧賽圖製藥有限公司預測 2025 年收入將增長 40%，預計達到人民幣 13.7 億至 13.9 億，淨利潤將激增 384% 至 444%，達到人民幣 1.624 億至 1.824 億。這一增長歸因於海外擴張和中國生物製藥行業的復甦。 | [Link](https://longbridge.com/en/news/274121607.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.